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Bacterial contamination of ex vivo stored platelets is a cause of transfusion-transmitted
infection. Violet-blue 405 nm light has recently demonstrated efficacy in reducing the
bacterial burden in blood plasma, and its operational benefits such as non-ionizing
nature, penetrability, and non-requirement for photosensitizing agents, provide a unique
opportunity to develop this treatment for in situ treatment of ex vivo stored platelets as a
tool for bacterial reduction. Sealed bags of platelet concentrates, seeded with low-level
Staphylococcus aureus contamination, were 405 nm light-treated (3–10 mWcm−2) up
to 8 h. Antimicrobial efficacy and dose efficiency was evaluated by quantification of
the post-treatment surviving bacterial contamination levels. Platelets treated with 10
mWcm−2 for 8 h were further evaluated for survival and recovery in severe combined
immunodeficient (SCID) mice. Significant inactivation of bacteria in platelet concentrates
was achieved using all irradiance levels, with 99.6–100% inactivation achieved by 8 h
(P < 0.05). Analysis of applied dose demonstrated that lower irradiance levels generally
resulted in significant decontamination at lower doses: 180 Jcm−2/10 mWcm−2 (P =
0.008) compared to 43.2 Jcm−2/3 mWcm−2 (P = 0.002). Additionally, the recovery of
light-treated platelets, compared to non-treated platelets, in themurinemodel showed no
significant differences (P = >0.05). This report paves the way for further comprehensive
studies to test 405 nm light treatment as a bactericidal technology for stored platelets.
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INTRODUCTION
Transfusion of ex vivo stored platelets (PLTs) is an essential and life-saving medical intervention
in bleeding, trauma, and surgery patients. Bacterially contaminated PLTs are associated with the
highest risk of transfusion transmitted infection in the USA, and can lead to septic transfusion
reactions (1, 2). Platelet transfusion products are particularly susceptible to contamination due to
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their storage at 22 ± 2◦C in gas permeable bags, under constant
agitation for 5–7 days post donation (3, 4).
Several methods have been implemented to reduce the risk of
bacterial contamination during blood donation including donor
questionnaires, skin disinfection, diversion of the initial blood
donation (5) and testing samples for bacterial contaminants (5,
6). However, there is still a residual risk of platelet contamination,
with ∼1 in 10,000 units testing positive for contamination, 1 in
100,000 causing transfusion reactions and 1 in 500,000 causing
fatal transfusion reactions (7).
According to US FDA regulations [21 CFR 606.145(a)],
blood establishments and transfusion services must assure that
the risk of bacterial contamination of platelets is adequately
controlled using FDA approved or cleared devices, or other
adequate and appropriate methods found acceptable for this
purpose by FDA. Acceptable methods include bacterial testing
or pathogen reduction technologies (PRTs) (8). Several PRTs
are approved or under investigation worldwide. This includes
Intercept system (Cerus Corporation, USA) which is an approved
PRT in the USA, that makes use of amotosalen followed by
UV-A (320–400 nm) irradiation for pathogen reduction (9).
There are two additional systems commonly studied: Mirasol
(TerumoBCT, USA), approved for use in other countries, which
combines riboflavin and broad-spectrumUV light (265–370 nm);
and Theraflex UV Platelets (Macopharma, France), currently
under development using 254 nm UV-C light (10, 11). However,
available PRTs do affect product quality in vitro and function
in vivo, following transfusion (12–14). The ideal PRT would
be relatively inexpensive, simple to implement and, with no
or minimal effect on the quality or efficacy of the transfusion
product (15).
Violet-blue light in the region of 405 nm could provide
a novel alternative PRT, without the need for additional
exogenous photosensitizers or extensive processing. These high-
intensity visible light photons excite endogenous porphyrins
within microbial cells, which causes an energy transfer and the
generation of reactive oxygen species. These toxic species cause
widespread oxidative damage to the pathogens, which ultimately
leads to death of pathogens (16–18). This decontamination
method has efficacy against a wide range of pathogenic organisms
including vegetative bacteria, spore forming bacteria and fungi
(17, 19, 20), with recent studies also demonstrating the potential
for inactivation of viruses, protozoa, and parasites (21–23).
Additionally, 405 nm light is safer than UV light wavelengths,
with antimicrobial efficacy capable of being achieved at levels that
are compatible with mammalian cells (16, 24–28).
A recent study (29) reported the successful reduction of
bacterial contamination within human blood plasma using
405 nm light, and significantly, demonstrated the capacity for
this decontamination treatment to be applied to the plasma
whilst in situ within the transfusion bag, highlighting a potential
operational advantage for this prospective PRT. Antiviral efficacy
has also been indicated, with successful reduction of a model
virus (calicivirus) in small volume plasma samples artificially
seeded with the virus (22).
The aim of the present study was to expand on the results
of these previous proof-of-concept studies, and investigate the
potential of this antimicrobial technique to be applied to human
platelet concentrates—which, as discussed, have a high potential
for bacterial contamination due to their standard storage at room
temperature conditions. The study investigated the efficacy of
405 nm light for decontamination of artificially-seeded platelet
suspensions, in situwithin transfusion bags, and also assessed the
compatibility of the visible light-treated platelets for transfusion
within a murine model.
MATERIALS AND METHODS
Human Platelets
Human PLTs (∼200mL bag volume) were obtained from the
Scottish National Blood Transfusion Service (SNBTS, UK), and
the National Institutes of Health Blood Bank (Bethesda, MD,
USA) and stored at 22 ± 2◦C under agitation. Study involving
human subjects protocol was approved by FDA Risk Involved
in Human Subjects Committee (RIHSC, Exemption Approval #
11-036B) and by the University of Strathclyde Ethics Committee
(UEC1011/31). Representative PLT samples were analyzed by
UV-Vis spectrophotometry (Biomate 5, Thermo Spectronic) to
determine the optical transmissibility of the PLTs between 300
and 500 nm, with transparency generally in the range of (>0.1–
<0.3%) between 400 and 405 nm (Figure 1A).
Bacterial Culture
Staphylococcus aureus NCTC 4135 (National Collection of Type
Cultures, Collindale, UK) was cultured in 100mL nutrient broth
(Oxoid Ltd, UK) at 37◦C under rotary conditions (120 rpm)
for 18 h. Broths were centrifuged at 3939 × g for 10min and
the pellet re-suspended in 100mL phosphate buffered saline
(PBS), and serially diluted for seeding into human PLT bags
at a concentration of 102 colony-forming units per milliliter
(CFU mL−1), in order to provide representative levels of low
density contamination.
405-nm Light Treatment
The 405 nm light sources used were light emitting diode
(LED) arrays (ENFIS PhotonStar Innovate UNO 24; PhotonStar
Technologies, UK) powered by a 40V Phillips Xitanium LED
Driver (Phillips, Netherlands), with a center wavelength of
405 nm and ∼10 nm FWHM (Figure 1B). The arrays were
bonded to heat sinks and fans, to ensure no thermal effects
on the exposed PLT samples. For PLT treatment, two 405 nm
LED arrays were held in a fixed position above the horizontally-
positioned platelet bag, with the optical output adjustable to
provide irradiances of between 3 and 10 mWcm−2 at the center
position of the PLT bag, taking into account a 20% reduction
in irradiance as the light transmits through the bag layer. Fixed
irradiances of∼3, 5, 7, and 10 mWcm−2 were used in this study,
with an example of the optical profile of the light distribution
across the transfusion bags, measured using a radiant power
meter and photodiode detector (LOT-Oriel Ltd., USA), shown
in Figure 1C. PLT bags were exposed to the fixed irradiances for
treatment times of up to 8 h, and the treatment dose (J cm−2) was
calculated as the product of the irradiance (W cm−2) multiplied
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FIGURE 1 | Optical characterization of human platelet concentrates, and the 405-nm light treatment system used for exposure of platelet concentrates. (A)
Transmission of human platelet concentrates. Analysis demonstrates the slight variation in optical properties between batches (n = 5). Measured by UV-Vis
spectrophotometry using a wavelength scan between 300 and 500 nm. (B) Optical emission spectrum of the 405-nm LED array, measured using a high resolution
spectrometer (HR4000 Ocean Optics Inc, Germany) and SpectraSuite software (Version 2.0.151). (C) Model demonstrating the irradiance profile across the area of
the platelet bag, with irradiance of ∼5 mWcm−2 at the center (plotted using MATLAB R2012b software).
by the exposure time (sec), with the irradiance value being the
maximum measured at the center position of the bag.
The experimental system was held in a shaking incubator
(72 rpm; 22–25◦C) to allow continuous sample agitation and
maintain exposure conditions. Seeded PLT bags were treated with
increasing exposures of 405 nm light. Control samples, which
were taken from the test samples before spiking, were held in
similar conditions, but shielded from the light. Post exposure,
samples were spread plated onto nutrient agar (Oxoid Ltd, UK)
using standard microbiological plating methods, and incubated
at 37◦C for 24 h. Surviving bacteria were then enumerated and
reported as % CFU survival compared to equivalent untreated
control samples. Data was statistically analyzed to assess for
significant differences between the % decontamination achieved
using differing irradiances at the same exposure time [P=<0.05,
one-way ANOVA with Fishers post-hoc test (Minitab v18)], and
to detect significant differences between treated and untreated
PLT samples [P =<0.05; two sample t test (Minitab v18)].
SCID Mice
Six week old female immunodeficient (SCID) mice were
obtained from the National Cancer Institute, Division of Cancer
Treatment, NIH. They were fed ad libitum and allowed to
acclimatize in a pathogen-free facility for a minimum of 7 days
before the experiments commenced. Animal protocols were in
compliance with guidelines provided by the Center of Biologics
Evaluation and Research Animal Research Advisory Committee.
Transfusion of Light-Treated Human PLTs
Into Mice and Mouse Whole Blood
Collection
Human PLTs (non-seeded) were exposed to 10 mWcm−2 light
treatment for 8 h (as described above). PLTs (∼1 × 109 PLTs
in 100 µL) were then infused into SCID mice as previously
described by Bosch-Marcé et al. (30) and Piper et al. (31). Briefly,
a 100 µL aliquot of concentrated human control PLTs or light-
treated PLTs (Test) was injected into the right lateral tail vein with
a 1-mL syringe fitted with a 27-gauge needle. At predetermined
time points, 30min, 2, 4, 6, 8, 10, and 24 h after transfusion,
small samples of whole blood were collected into heparinized
capillary tubes (Fisher Scientific, Pittsburgh, PA) from the left
lateral tail vein using a tail vein nick technique, and the human
PLT recovery in circulation was determined immediately, after
incubation with a monoclonal antibody or an isotype control,
using flow cytometry. The amount of PLTs recovered at 30min
after infusion was set as the 100% recovery.
Flow Cytometric Detection of Human PLTs
Human PLTs in mouse whole blood were detected with
a monoclonal anti-human CD41-FITC–conjugated antibody
(Clone P2; Beckman Coulter, Brea, CA) using a flow cytometer
as previously described by Bosch-Marcé et al. (30) and Piper
et al. (31). Briefly, the blood samples and the antibody were
incubated for 20min at RT in the dark. After the incubation
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period, the samples were washed twice and centrifuged for 5min
at 1,000 × g, the supernatant was removed, and the cells were
resuspended in PBS containing 0.1% bovine serum albumin. The
samples were analyzed with a flow cytometer (FACSCalibur, BD
Biosciences, San Diego, CA). The human PLTs were used to
establish a gate based on forward (FSC) and side (SSC) scatter,
which would detect the majority of the transfused PLTs. This
gate was then used to acquire 25,000 PLT events from collected
mouse whole blood. An ungated FSC vs. SSC density plot of
mouse whole blood verified that the PLT population in the
sample fell within the gate established from the human PLT
sample. PLT recovery was defined as the percentage of anti-
human CD41-FITC–positive gated events in the sample of mouse
whole blood. Each mouse was its own control and therefore,
for each mouse, the amount of PLTs recovered at 30min after
infusion was set as the 100% recovery for all subsequent time
points. Data was analyzed [P > 0.05; paired t test (Minitab
v18)] to determine any significant differences between the light-
treated (n = 12) and non-light treated, control, PLTs (n = 14).
Since we consistently observed negligible amounts of human
PLTs at 24 h in all treatments, only data up to 10 h were analyzed
for significance.
RESULTS
Figure 2 demonstrates the efficacy of 405 nm light for
decontamination of PLT bags seeded with low density S.
aureus, using the 4 fixed irradiance levels, over time. It can
be seen that at all light irradiances used, successful reduction
of the bacterial contamination was achieved. By 8 h exposure
<0.5% contamination was detected with all irradiances used.
Analysis of the inactivation kinetics of each of the 4 irradiances,
demonstrated that inactivation was most effective with the
highest, 10 mWcm−2, irradiance: contamination levels decreased
in a constant downward trend from 1 h, with 0.3% remaining
by 8 h. With the other 3 irradiances used, contamination levels
remained consistent over the first 4 h, with the majority of the
inactivation (>92.5%) achieved by 6 h exposure—similar to
the 10 mWcm−2 treatment. Statistical analysis demonstrated
that, at most exposure times (1–4, 6, and 8 h), the levels of
bacterial inactivation achieved were statistically similar despite
the use of different irradiance levels (P > 0.05). The sample-to-
sample variation in PLT transmissibility (Figure 1A) is likely a
contributing factor to the degree of deviation observed in some
of the inactivation data, and consequently impacting statistical
analysis. Regardless, significant differences in the degree of
inactivation achieved at fixed time periods were detected at 5 h (P
= 0.001), and 7 h (P= 0.006) (Figure 2). Bacterial contamination
in non-treated control samples, showed no decrease over the
8 h period.
Although the levels of inactivation achieved over the 8 h
exposure period were comparable when using the 4 irradiance
levels (3, 5, 7, 10 mWcm−2), the dose levels were found to be
quite different. Figure 3 demonstrates the inactivation kinetics
of the different irradiances as a function of dose (Jcm−2). The
highest dose levels were used when exposing the PLTs to the
FIGURE 2 | Comparison of the decontamination efficacy of varying irradiances
of 405 nm light for decontamination of ex vivo stored human platelet
concentrates, as a function of time. Platelet transfusion bags were seeded
with low density contamination (102 CFUml−1 Staphylococcus aureus) under
constant agitation (72 rpm; 22–25◦C). Data represents mean ± SEM (n = >3),
with % survival compared to untreated (0 Jcm−2 ) platelet samples. (*) represent
significantly different % decontamination compared to other irradiances at the
same exposure time [P = <0.05, one-way ANOVA with Fishers post-hoc test
(Minitab v18)]: *a, significantly different to all other irradiances; *b, significantly
different to 5 & 10 mWcm−2; *c, significantly different to 3 & 5 mWcm−2.
highest irradiance of 10 mWcm−2, ranging from 36 Jcm−2
(1 h treatment) to 288 Jcm−2 (8 h treatment), with significant
reductions achieved by 5 h/180 Jcm−2 (P = 0.008). As the
fixed irradiance decreased, so did the applied dose levels, with
irradiances of 7, 5, and 3 mWcm−2 giving doses ranging from
25 to 201, 18 to 144, and 10.8 to 86 Jcm−2, respectively.
Results demonstrate that, generally, use of the lower irradiance
levels, resulted in statistically significant reductions in bacterial
contamination at lower applied doses: 126 Jcm−2 using 7
mWcm−2 (P = 0.009); 72 Jcm−2 using 5 mWcm−2 (P = 0.003),
and 43.2 Jcm−2 using 3 mWcm−2 (P = 0.002).
To evaluate whether the treatment of human PLTs with
405 nm light had an effect on their recovery, PLTs were exposed to
10mWcm−2 light for 8 h, and the in vivo recovery of human PLTs
in SCID mice was then analyzed. In Figure 4, recovery of the
human PLTs show that treatment with antimicrobial 405 nm light
had minimal effect on the recovery of human PLTs in the SCID
mice when compared to the control, non-treated human PLTs,
with no significant differences detected at any of the tested time
points (2–10 h; P = >0.05). Additional testing using PCs light
treated for 12 h instead of 8 h demonstrated that PLT recovery
was very similar to those that had been treated for 8 h (n = 5 for
test group, n= 5 for control group; data not shown).
DISCUSSION
The results of this study has provided the proof of concept for
bactericidal efficacy and cellular safety margin of 405 nm violet-
blue light on ex vivo stored human platelets spiked with S.
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FIGURE 3 | Decontamination of ex vivo stored human platelet suspensions using 405 nm light, as a function of dose. Platelet transfusion bags were seeded with low
density contamination (102 CFUml−1 S. aureus) and exposed to irradiances of approximately (A) 10 mWcm−2, (B) 7 mWcm−2, (C) 5 mWcm−2, and (D) 3 mWcm−2,
under constant agitation (72 rpm; 22–25◦C). Data represents mean ± SEM (n = >3), with % survival and significant (*) decontamination calculated compared to
untreated (0 Jcm−2 ) samples [P = <0.05; paired t test (Minitab v18)].
aureuswhilst held within sealed transfusion bags. Use of relatively
low irradiances of 405 nm light (3–10 mWcm−2) were shown
to be effective for bactericidal activity over treatment periods
of up to 8 h. Additionally, PLT concentrates which had been
exposed to the maximum treatment (10 mWcm−2 for 8 h), also
demonstrated in vivo recovery in a murine model similar to that
of non-treated PLTs.
All four irradiances levels used in the study (3, 5, 7, and 10
mWcm−2) achieved good bactericidal effects, with consistent
trends of inactivation rates: >92.5% reduction by 6 h, and >99%
reduction by 8 h. Although there was, in the most part, no
significant difference in the levels of inactivation achieved at each
exposure time with the different irradiance levels, trends were
observed. Use of 10 mWcm−2 light, resulted in the most linear
inactivation kinetics, with inactivation at the lower irradiances
(3, 5, 7 mWcm−2) displaying a more linear, and indeed upward,
initial trend (up to 3–4 h) before inactivation became evident
(∼5 h onwards). It is possible that this difference in kinetics may
be due to the fact that at the lower irradiances, the low density
bacterial contaminants are slower to be affected by the light
treatment, and are able to persist and, to some extent, potentially
replicate, in these early stages, with room temperature storage
providing adequate conditions for growth.
Interestingly, the inactivation kinetics observed for platelets
are very similar to those shown for human plasma in a previous
study by the authors (29). The study demonstrated use of 5
mWcm−2 405 nm light for treatment of pre-bagged human blood
plasma, with contamination levels remaining steady up till a
treatment dose of 90 Jcm−2 (as shownwith the same irradiance in
the present study), followed by significant decontamination being
achieved with doses ≥108 Jcm−2. This similarity in inactivation
rates between platelets and plasma is of great interest, particularly
when looking at their comparative optical transmissibility.
Analysis of human PLT samples (n = 5) demonstrated low
transmissibility of 405 nm light, with variation in transmission
of between 0.1 and 0.2%. The transmissibility of plasma tends
to be slightly greater (1–2%) in the region of 405 nm (29). With
this low transmissibility, and also when observing the non-
uniform optical profile over the area of the PLT bags, continuous
agitation of the bags during light treatment is important to ensure
uniform mixing of the PLT contaminants, and prevents shading
of contaminants at the lower depths of the PLT concentrates.
Analysis of the applied optical doses used for decontamination
highlighted that although successful inactivation was achieved
using each of the 4 irradiance levels, the doses required to
achieve this inactivation varied greatly. Whilst the levels of
inactivation achieved at each of the treatment times were
generally comparable despite the different light irradiances
used (3, 5, 7, 10 mWcm−2), the applied dose levels are quite
different. Using 6 h exposure as an example (Figure 3), it can
be seen that the doses required to achieve the same >92.5%
reduction vary depending on the irradiance level used—ranging
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FIGURE 4 | In vivo recovery of human platelets (PLTs) in SCID mice. PLTs were
treated with 10 mWcm−2 405 nm light for 8 h before transfusion into SCID
mice. The % of initial recovery of non-treated (n = 14 ± SEM) and light-treated
(n = 12 ± SEM) PLTs was monitored over time, up to 24 h. Negligible amounts
of human PLTs were consistently observed at 24 h in all treatments, therefore
only data up to 10 h were analyzed for significance. Results demonstrated no
significant difference [P > 0.05; two sample t test (Minitab v18)] between the
light-treated and non-light treated (control) PLTs.
from 64.8 Jcm−2 (when using 3 mWcm−2) up to 216 Jcm−2
(using 10 mWcm−2). When this is considered in relation to
the antimicrobial mechanism of action, it is likely that this
improved efficiency at lower irradiance levels is due to the
ratio of photons to intracellular porphyrins: there will be
a threshold of the number of photons that can actively be
involved in photoexcitation of the endogenous intracellular
porphyrins at any given time, and above this there is likely
a point at which the absorption of more photons will have
little effect on the inactivation mechanism already in progress
(32). For practical application, it will be important to evaluate
any potential implications of these excess photons, in order to
ensure that there is no detrimental effect to the PLT integrity
due to concurrent photoexcitation of any other photo-sensitive
components within the PLT concentrates themselves, in addition
to assessing electrical and optical efficiencies.
As a proof-of-concept, this study used Staphylococcus aureus
as the model organism for antimicrobial testing. Previous studies
have demonstrated the bactericidal efficacy of 405 nm light for a
limited selection of Gram-positive (S. aureus and Staphylococcus
epidermidis) and Gram-negative bacteria (Escherichia coli), and
also viruses (feline calicivirus) within blood plasma (22, 29).
Based on these studies, we believe, that similar inactivation
efficacy would be achieved in PLT concentrates, particularly given
the similar inactivation kinetics observed for S. aureus between
this study and the previous work by the authors (29). However,
as the susceptibility of a bacterial species to a specific photo-
inactivation method can vary between strains, future work will
employ a panel of different bacterial species and strains that
are recommended by the World Health Organization (WHO)
in order to validate this technology for PLT safety from blood
borne bacteria and other microbes. In addition to this, expanding
testing to include antimicrobial evaluation against both high and
low concentrations of bacterial contamination will be important
to evaluate inactivation kinetics, and demonstrate the potential
for maintaining sterility, respectively, to the end of product’s
shelf life.
While with current PRTs, the germicidal efficiency of
photodynamic inactivation using UV-light coupled with a
photosensitizer is higher than that of 405 nm violet-blue light
alone, the use of 405 nm light does have a number of envisaged
operational and safety advantages. Violet-blue light utilizes non-
ionizing light, and this is of practical interest as there are some
concerns that ionizing UV light can potentially lower platelet
recovery and decrease the recirculation of pathogen inactivated-
treated platelets (9, 33). It is thought that, at some levels, UV
light can damage platelet mRNA and ribosomal machinery that
is required for protein synthesis and affect platelet proteins
(particularly fibrinogen receptors), as well as application of fast
dose rates producing high temperatures that can hinder platelet
function (33). In the case of 405 nm light treatment, further
biochemical and molecular evaluations of the platelet integrity
are required in order to gain a broader understanding of the
cellular interactions with photons of this wavelength at a range
of irradiances and exposure times, however the proof of concept
demonstrated in this study in a murine model, that the treatment
conditions used (10 mWcm−2 for 8 h/288 Jcm−2) were not
detrimental to the platelets compared to that of non-treated
platelets, demonstrates its potential for bacterial inactivation of
PLT suspensions.
The observation that 405 nm light can in situ inactivate
bacteria in bagged PLTs, without the requirement for additional
chemical additives, will have significant operational advantages in
terms of reducing processing requirements, which consequently
would reduce opportunities for bacterial contamination to be
introduced, and potentially reduce loss of platelets due to surface
binding to the containers during processing (9, 33). Technologies
utilizing UV-light typically require the PLTs to be transferred to
UV-transmissible bags prior to treatment, and the photosensitive
chemical additive to be removed following illumination, resulting
in further processing and minimal residues within the PLT
concentrates (9, 33). Violet-blue light treatment would not
require these processing stages.
Currently in the U.S., platelets can be stored for 5–7 days
however after accounting for time required for viral screening,
bacterial detection, and shipping to transfusion location, the
effective shelf life is typically shorter (34). Therefore, future
investigations should focus on the potential for pathogen
reduction treatment using 405 nm light to improve the safety
and shelf life of PLT concentrates, either through low irradiance
continuous exposure throughout the storage period, or as pre-
storage PRT. This could reduce the volume of wasted platelet
donations: currently 4–16% of collected platelets are wasted
because they do not find a recipient within their limited shelf-
life (34).
Overall, this study has successfully provided a proof of
concept that 405 nm light has the potential to be considered
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as a technology for bacterial reduction in stored human blood
platelets. Both this study, and the previous work on the potential
of 405 nm light for decontamination of blood plasma (29), have
utilized small scale systems for product treatment, and there are
a variety of both antimicrobial and hematological investigations,
and technological challenges, which will need to be investigated
in order to fully evaluate the compatibility and practicality of
this antimicrobial technology. However, the penetrability and
non-ionizing nature of 405 nm light, and the non-requirement
for photosensitizing agents, provide unique benefits for 405 nm
violet-blue light as a technology for in situ treatment of ex vivo
stored platelets.
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